About
- About Avecho
- Board & Leadership
TPM^® Technology
Portfolio
Invest
- Investor Centre
- Media Centre
Contact

Hit enter to search or ESC to close

Phosphagenics Appoints Three New Directors

April 13, 2015

click here to read more

Post navigation

Phosphagenics signs license agreement to expand TPM®-based animal nutrition products to the UK and Ireland

Phosphagenics Initiates Oxycodone Patch Dosing in Phase 2 Clinical Trial

Related Posts

Avecho reaches two-year stability milestone for its CBD softgel capsule

June 22, 2023June 22, 2023

Athenex takes Avecho’s Vitamin K injection to FDA pre-IND meeting

January 12, 2023January 12, 2023

Research report | RaaS Watchlist: Waking the Sleeping Giant

August 26, 2025August 26, 2025

Recent Posts

Recruitent recommences for phase III insomnia trial
August 31, 2026
Euroz Hartleys | Successful Phase 3 Interim Results
July 8, 2026
Avecho Phase III insomnia trial advances following positive interim analysis
June 24, 2026

Categories

Analyst Coverage
Company Announcement
Company Report
Investor Webinar
Media Coverage
Newsletter
Press Release
Uncategorised

About us

We see a future where more patients can get even more from their treatments through innovative delivery technologies.

Stay Posted

Stay informed about our latest news and developments.

Leave this field empty if you're human:

About Avecho

TPM^® Technology

Portfolio

Investor Centre
- Investor Centre
- Media Centre

© Copyright 2019 Avecho Biotechnology Ltd.